TAS-303
10060050
Phase 2 small_molecule completed
Quick answer
TAS-303 for Stress Urinary Incontinence is a Phase 2 program (small_molecule) at Taiho Pharma Netherlands B.V. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Taiho Pharma Netherlands B.V.
- Indication
- Stress Urinary Incontinence
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed